Abstract Number: 1422 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis
Background/Purpose: Iguratimod is a newly-developed disease-modifying antirheumatic drug (DMARD) that was approved in Japan in September 2012. It has been reported to suppress tumor necrosis…Abstract Number: 1423 • 2013 ACR/ARHP Annual Meeting
The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis
Background/Purpose : The impact of Body mass Index (BMI) on efficacy of TNF blocking therapy is an important question, as adipose tissue appears to have…Abstract Number: 1424 • 2013 ACR/ARHP Annual Meeting
Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare
Background/Purpose: A limited number of rheumatoid arthritis (RA) patients are managed with a single disease-modifying anti-rheumatic drug (DMARD). Previous studies have suggested that DMARD naïve…Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…Abstract Number: 1426 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Spermidine/Spermine N1-Acetyltransferase Activity – a New Therapeutical Concept In Rheumatoid Arthritis
Background/Purpose: Spermine/spermidine N1-acetyltransferase (SSAT1) and polyamine modulating factor 1 (PMF1) are increased in rheumatoid arthritis synovial fibroblasts (RASF). Since PMF1 regulates the expression of SSAT1,…Abstract Number: 1427 • 2013 ACR/ARHP Annual Meeting
Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a serious autoimmune disease that significantly impacts patients’ quality of life. Several approved biologic drugs targeting tumor necrosis factor (TNF)…Abstract Number: 1428 • 2013 ACR/ARHP Annual Meeting
The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA)
Background/Purpose: The BREVACTA study assessed the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) in pts with moderate to severe RA who had an inadequate response…Abstract Number: 1429 • 2013 ACR/ARHP Annual Meeting
Adiponectin Levels Are Increased After Tocilizumab Therapy Among Adults With Rheumatoid Arthritis: Results From The Measure Study
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients (pts) with rheumatoid arthritis (RA). Adiponectin has been shown to have anti-inflammatory and…Abstract Number: 1431 • 2013 ACR/ARHP Annual Meeting
Algorithms Using Genome-Wide SNP Analysis For Prediction Of Efficacy and Adverse Events Of Abatacept Using Two Population Samples From Multiple Medical Cohorts
Background/Purpose: Abatacept (ABT), a CTLA4-Ig fusion protein agent targeted to T-cells, is a relatively new biological agent for RA treatment in Japan. However, there is…Abstract Number: 1432 • 2013 ACR/ARHP Annual Meeting
The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry
Background/Purpose: Serious infections in patients with rheumatoid arthritis (RA) treated with rituximab (RTX) are slightly more frequent in common practice than in clinical trials. Morevover,…Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…Abstract Number: 1434 • 2013 ACR/ARHP Annual Meeting
Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency
Background/Purpose: Bayesian style network meta-analyses and mixed treatment comparisons help address potential bias from effect modifying trial covariates within indirect comparisons and are theoretically easier…Abstract Number: 1435 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of TNF-á Inhibitor Therapy Does Not Differ Between Elderly and Younger Patients With Rheumatoid Arthritis: Results From The Corrona Registry
Background/Purpose: Biologics have revolutionized the therapy and prognosis of patients (pts) with Rheumatoid Arthritis (RA). Studies evaluating whether the effectiveness of TNF-α inhibitor (TNFi) therapy…Abstract Number: 1436 • 2013 ACR/ARHP Annual Meeting
Early Changes In a Multi-Biomarker Disease Activity Score After Starting Adalimumab Treatment Predict Change In MRI Inflammation At 6 Months
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been validated as a measure of disease activity in rheumatoid arthritis. This study aimed to see if…Abstract Number: 1397 • 2013 ACR/ARHP Annual Meeting
Changes In MMP In Fibroblast-Like Synoviocytes Following Adipogenesis
Background/Purpose: Fibroblast-like synovial cells (FLS) play important roles in the disease progression of RA. FLS produce cytokines and chemokines that contribute to chronic inflammation…